Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Aug;66(2):323–330. doi: 10.1038/bjc.1992.264

The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.

P K Quinn 1, M C Bibby 1, J A Cox 1, S M Crawford 1
PMCID: PMC1977797  PMID: 1503906

Abstract

We have studied the influence of the peripheral vasodilator hydralazine (HDZ) on the vasculature and blood perfusion of two members of a series of subcutaneous murine adenocarcinomata of the colon (MAC tumours), and the influence of HDZ on the efficacy and/or toxicity of TCNU and melphalan. The fluorescent DNA stain Hoechst 33342, showed that HDZ caused a shutdown of tumour vasculature, related in magnitude to both dose and tumour differentiation state; 10 mg kg-1 caused an 80% vascular shutdown of well differentiated MAC 26 tumours, but only a 50% shutdown of the poorly differentiated MAC 15A tumours. 2.5 mg kg-1 was ineffective. The blood perfusion marker 99mTc-HMPAO showed that the normal perfusion of MAC tumours was consistently markedly less than that of lung, liver or kidneys (4-5% of lung perfusion). HDZ (10 mg kg-1) decreased MAC 26 perfusion by 63%, and that of MAC 15A by 20%. Again, 2.5 mg kg-1) was ineffective. Use of in vivo to in vitro clonogenic assays showed that HDZ (10 mg kg-1) potentiated the efficacy of melphalan (1-10 mg kg-1 i.p.) by a factor of 2.1, and increased the efficacy of TCNU (1-10 mg kg-1 i.v., factor = 1.7) when given 10 or 15 min respectively after dosing. However, the addition of HDZ increased the acute bone marrow toxicity of melphalan, but not that of TCNU. The clinical relevance of these results is discussed.

Full text

PDF
329

Images in this article

326Figure 1
on p.326

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALGIRE G. H., LEGALLAIS F. Y. Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumors. J Natl Cancer Inst. 1951 Oct;12(2):399–421. [PubMed] [Google Scholar]
  2. Babbs C. F., DeWitt D. P., Voorhees W. D., McCaw J. S., Chan R. C. Theoretical feasibility of vasodilator-enhanced local tumor heating. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1137–1146. doi: 10.1016/0277-5379(82)90095-5. [DOI] [PubMed] [Google Scholar]
  3. Bibby M. C., Double J. A., Morris C. M. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1361–1364. doi: 10.1016/0277-5379(88)90229-5. [DOI] [PubMed] [Google Scholar]
  4. Bibby M. C., Loadman P. M., al-Ghabban A. F., Double J. A. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br J Cancer. 1992 Mar;65(3):347–350. doi: 10.1038/bjc.1992.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bibby M. C., Phillips R. M., Double J. A. Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol. 1989;24(2):87–94. doi: 10.1007/BF00263126. [DOI] [PubMed] [Google Scholar]
  6. Chan R. C., Babbs C. F., Vetter R. J., Lamar C. H. Abnormal response of tumor vasculature to vasoactive drugs. J Natl Cancer Inst. 1984 Jan;72(1):145–150. doi: 10.1093/jnci/72.1.145. [DOI] [PubMed] [Google Scholar]
  7. Chaplin D. J., Acker B., Olive P. L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1131–1135. doi: 10.1016/0360-3016(89)90267-8. [DOI] [PubMed] [Google Scholar]
  8. Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
  9. D'Incalci M., Citti L., Taverna P., Catapano C. V. Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev. 1988 Dec;15(4):279–292. doi: 10.1016/0305-7372(88)90026-6. [DOI] [PubMed] [Google Scholar]
  10. Double J. A., Ball C. R. Chemotherapy of transplanted adenocarcinomas of the colon in mice. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1083–1089. [PubMed] [Google Scholar]
  11. Double J. A., Ball C. R., Cowen P. N. Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst. 1975 Jan;54(1):271–275. doi: 10.1093/jnci/54.1.271. [DOI] [PubMed] [Google Scholar]
  12. Double J. A., Bibby M. C., Loadman P. M., Bloomer J. C. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1355–1360. doi: 10.1016/0277-5379(88)90228-3. [DOI] [PubMed] [Google Scholar]
  13. Ell P. J., Hocknell J. M., Jarritt P. H., Cullum I., Lui D., Campos-Costa D., Nowotnik D. P., Pickett R. D., Canning L. R., Neirinckx R. D. A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease. Nucl Med Commun. 1985 Aug;6(8):437–441. doi: 10.1097/00006231-198508000-00002. [DOI] [PubMed] [Google Scholar]
  14. Field S. B., Needham S., Burney I. A., Maxwell R. J., Coggle J. E., Griffiths J. R. Differences in vascular response between primary and transplanted tumours. Br J Cancer. 1991 May;63(5):723–726. doi: 10.1038/bjc.1991.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gundersen S., Dombernowsky P., Cavalli F., Bruntsch U., Renard J., Van Glabbeke M., Pinedo H. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group. Eur J Cancer Clin Oncol. 1989 Jul;25(7):1095–1097. doi: 10.1016/0277-5379(89)90394-5. [DOI] [PubMed] [Google Scholar]
  16. Hammersley P. A., McCready V. R., Babich J. W., Coghlan G. 99mTc-HMPAO as a tumour blood flow agent. Eur J Nucl Med. 1987;13(2):90–94. doi: 10.1007/BF00256023. [DOI] [PubMed] [Google Scholar]
  17. Hirst D. G., Hirst V. K., Joiner B., Prise V., Shaffi K. M. Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate. Br J Cancer. 1991 Jul;64(1):54–58. doi: 10.1038/bjc.1991.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Holmes R. A., Chaplin S. B., Royston K. G., Hoffman T. J., Volkert W. A., Nowotnik D. P., Canning L. R., Cumming S. A., Harrison R. C., Higley B. Cerebral uptake and retention of 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO). Nucl Med Commun. 1985 Aug;6(8):443–447. doi: 10.1097/00006231-198508000-00003. [DOI] [PubMed] [Google Scholar]
  19. Horsman M. R., Christensen K. L., Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia. 1989 Mar-Apr;5(2):123–136. doi: 10.3109/02656738909140442. [DOI] [PubMed] [Google Scholar]
  20. Jirtle R. L. Chemical modification of tumour blood flow. Int J Hyperthermia. 1988 Jul-Aug;4(4):355–371. doi: 10.3109/02656738809016490. [DOI] [PubMed] [Google Scholar]
  21. Kalmus J., Okunieff P., Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors. Cancer Res. 1990 Jan 1;50(1):15–19. [PubMed] [Google Scholar]
  22. Lee F. Y., Workman P. Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol. 1986;17(1):30–37. doi: 10.1007/BF00299862. [DOI] [PubMed] [Google Scholar]
  23. Murray J. C., Randhawa V., Denekamp J. The effects of melphalan and misonidazole on the vasculature of a murine sarcoma. Br J Cancer. 1987 Mar;55(3):233–238. doi: 10.1038/bjc.1987.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Okunieff P., Walsh C. S., Vaupel P., Kallinowski F., Hitzig B. M., Neuringer L. J., Suit H. D. Effects of hydralazine on in vivo tumor energy metabolism, hematopoietic radiation sensitivity, and cardiovascular parameters. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1145–1148. doi: 10.1016/0360-3016(89)90270-8. [DOI] [PubMed] [Google Scholar]
  25. Phillips R. M., Bibby M. C., Double J. A. In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1365–1371. doi: 10.1016/0277-5379(88)90230-1. [DOI] [PubMed] [Google Scholar]
  26. Randhawa V. S., Stewart F. A., Denekamp J., Stratford M. R. Factors influencing the chemosensitization of melphalan by misonidazole. Br J Cancer. 1985 Feb;51(2):219–228. doi: 10.1038/bjc.1985.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rowell N. P., Flower M. A., McCready V. R., Cronin B., Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiother Oncol. 1990 Aug;18(4):283–292. doi: 10.1016/0167-8140(90)90108-9. [DOI] [PubMed] [Google Scholar]
  28. SAPIRSTEIN L. A. Fractionation of the cardiac output of rats with isotopic potassium. Circ Res. 1956 Nov;4(6):689–692. doi: 10.1161/01.res.4.6.689. [DOI] [PubMed] [Google Scholar]
  29. Siemann D. W. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br J Cancer. 1990 Sep;62(3):348–353. doi: 10.1038/bjc.1990.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Smith K. A., Hill S. A., Begg A. C., Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer. 1988 Mar;57(3):247–253. doi: 10.1038/bjc.1988.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Smyth J. F., Macpherson J. S., Warrington P. S., Kerr M. E., Whelan J. M., Cornbleet M. A., Leonard R. C. Phase I study of TCNU, a novel nitrosourea. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1845–1849. doi: 10.1016/0277-5379(87)90050-2. [DOI] [PubMed] [Google Scholar]
  32. Stratford I. J., Adams G. E., Godden J., Nolan J., Howells N., Timpson N. Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer. 1988 Aug;58(2):122–127. doi: 10.1038/bjc.1988.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. THOMLINSON R. H., GRAY L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955 Dec;9(4):539–549. doi: 10.1038/bjc.1955.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  35. Trotter M. J., Acker B. D., Chaplin D. J. Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785–789. doi: 10.1016/0360-3016(89)90067-9. [DOI] [PubMed] [Google Scholar]
  36. Trotter M. J., Olive P. L., Chaplin D. J. Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer. 1990 Dec;62(6):903–908. doi: 10.1038/bjc.1990.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer. 1988 Jul;58(1):109–113. doi: 10.1038/bjc.1988.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Voorhees W. D., 3rd, Babbs C. F. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol. 1982 Oct;18(10):1027–1033. doi: 10.1016/0277-5379(82)90252-8. [DOI] [PubMed] [Google Scholar]
  39. Wiig H., Tveit E., Hultborn R., Reed R. K., Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest. 1982 Apr;42(2):159–164. [PubMed] [Google Scholar]
  40. Workman P. TCNU: a ray of hope for designer nitrosoureas? Eur J Cancer Clin Oncol. 1987 Dec;23(12):1823–1828. doi: 10.1016/0277-5379(87)90046-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES